Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
Delayed Quote. Delayed Swiss Exchange - 08/16 11:30:15 am
87.52 CHF   +1.23%
07:15aNOVARTIS : CEO Battles Fallout From Data Manipulation
DJ
08/16EUROPE MARKETS: After Wild Week, Europe Stocks Trade Higher
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

“Multifocal Diffractive Ophthalmic Lens” in Patent Application Approval Process (USPTO 20190224001): Novartis AG

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:00pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Pharma Business Daily -- A patent application by the inventors Choi, Myoung-taek (Arlington, Tx); Hong, Xin (Fort Worth, Tx); Liu, Yueai (Arlington, Tx), filed on April 2, 2019, was made available online on July 25, 2019, according to news reporting originating from Washington, D.C., by NewsRx correspondents.

This patent application is assigned to Novartis AG (Basel, Switzerland).

The following quote was obtained by the news editors from the background information supplied by the inventors: “The human eye functions to provide vision by refracting light through a clear outer portion called the cornea, and refracting the light by way of a crystalline lens onto a retina. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens. When age or disease causes the lens to become aberrated, vision deteriorates because of the loss of retinal image quality. This loss of optical quality in the lens of the eye is medically known as a cataract. An accepted treatment for this condition is surgical removal of the lens and replacement of the lens function by an artificial intraocular lens (IOL). As the eye ages, it may also lose the ability to change focus to nearer focal points, known as accommodation. This loss of accommodation with age is known as presbyopia.

“In the United States, the majority of cataractous lenses are removed by a surgical technique called phacoemulsification. During this procedure, a portion of the anterior capsule is removed and a thin phacoemulsification cutting tip is inserted into the diseased lens and vibrated ultrasonically. The vibrating cutting tip liquefies or emulsifies the nucleus and cortex of the lens so that the lens may be aspirated out of the eye. The diseased nucleus and cortex of the lens, once removed, is replaced by an artificial intraocular lens (IOL) in the remaining capsule (in-the-bag). In order to at least partially restore the patient’s ability to see in focus at near distances, the implanted IOL may be a multifocal lens.

“One common type of multifocal lens is a diffractive lens, such as a bifocal lens providing distance vision and near (or intermediate) vision. Trifocal diffractive lenses are also available that provide an additional focal point and, at least potentially, a broader range of in-focus vision. However, there are disadvantages associated with dividing light energy among multiple focal points, particularly in trifocal lenses. Thus, there remains a need for improved multifocal diffractive lenses.”

In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventors’ summary information for this patent application: “In various embodiments of the invention, a multifocal ophthalmic lens includes an ophthalmic lens and a diffractive element. The ophthalmic lens has a base curvature corresponding to a base power. The diffractive element produces constructive interference in at least four consecutive diffractive orders corresponding to a range of vision between near and distance vision. The constructive interference produces a near focus, a distance focus corresponding to the base power of the ophthalmic lens, and an intermediate focus between the near focus and the distance focus.

“Other features and advantages of various embodiments of the present invention will be apparent to one skilled in the art from the following description.”

The claims supplied by the inventors are:

“1. An intraocular lens, comprising: a lens having an anterior surface and a posterior surface; and a diffractive profile disposed on at least one of the anterior surface and the posterior surface, the diffractive profile comprising a plurality of annular zones configured to produce constructive interference in at least four consecutive diffractive orders within a range of vision, the four consecutive diffractive orders including a lowest diffractive order, a far-intermediate diffractive order, a near-intermediate diffractive order, and a highest diffractive order, wherein: the highest diffractive order corresponds to a near focus for near vision, a lowest diffractive order corresponds to a distance focus for distance vision, the far-intermediate diffractive order corresponds to an far-intermediate focal point, and the near-intermediate diffractive order corresponds to a near-intermediate focal point.

“2. The intraocular lens of claim 1, wherein a diffraction efficiency of the lowest diffractive order is greater than a diffraction efficiency of any other of the consecutive diffractive orders.

“3. The intraocular lens of claim 2, wherein, a diffraction efficiency of each of the each of the far-intermediate diffractive order and the near-intermediate diffractive order is in the range of 10-20%.

“4. The intraocular lens of claim 2, wherein a diffraction efficiency of each of the highest diffractive order, the far-intermediate diffractive order, and the near-intermediate diffractive order is in the range of 10-20%.

“5. The intraocular lens of claim 2, wherein a diffraction efficiency of the highest diffractive order is greater than a diffraction efficiency of at least one of the far-intermediate diffractive order and the near-intermediate diffractive order.

“6. The intraocular lens of claim 2, wherein, a diffraction efficiency of one of at least one of the far-intermediate diffractive order and the near-intermediate diffractive order is less than 10%.

“7. The intraocular lens of claim 2, a diffraction efficiency of the far-intermediate diffractive order is less than 10%.

“8. The intraocular lens of claim 2, a diffraction efficiency of the near-intermediate diffractive order is less than 10%.

“9. The intraocular lens of claim 2, wherein a diffraction efficiency of the far-intermediate diffractive order is greater than a diffraction efficiency of the near-intermediate diffractive order.

“10. The intraocular lens of claim 2, wherein a diffraction efficiency of the near-intermediate diffractive order is greater than a diffraction efficiency of the far-intermediate diffractive order.

“11. The intraocular lens of claim 1, wherein the near focus, the near-intermediate focal point, and the far-intermediate focus each correspond to a different add power relative to a base power of the distance focus; an add power corresponding to the far-intermediate focus is less than one half of an add power corresponding to the near focus; and an add power corresponding to the near-intermediate focus is greater than one half of the add power corresponding to the near focus.

“12. The intraocular lens of claim 1, wherein the near-intermediate focal point corresponds to vision at 40 cm and the far-intermediate focal point corresponds to vision at 60 cm.

“13. The intraocular lens of claim 1, wherein the four consecutive diffractive orders comprise at least the +2 diffractive order and the +3 diffractive order.

“14. The intraocular lens of claim 1, wherein the four consecutive diffractive orders are (0, +1, +2, +3).

“15. The intraocular lens of claim 1, wherein the lowest diffractive order is a 0.sup.th diffractive order.

“16. The intraocular lens of claim 1, wherein the lowest diffractive order is higher than a 0.sup.th diffractive order.

“17. The intraocular lens of claim 1, wherein the plurality of annular zones comprise diffractive steps.

“18. The intraocular lens of claim 17, wherein the diffractive steps repeat.”

URL and more information on this patent application, see: Choi, Myoung-taek; Hong, Xin; Liu, Yueai. Multifocal Diffractive Ophthalmic Lens. Filed April 2, 2019 and posted July 25, 2019. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220190224001%22.PGNR.&OS=DN/20190224001&RS=DN/20190224001

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, NewsRx Pharma Business Daily, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
07:15aNOVARTIS : CEO Battles Fallout From Data Manipulation
DJ
08/16EUROPE MARKETS: After Wild Week, Europe Stocks Trade Higher
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/14NOVARTIS : Correction to Story on Executive Changes at Novartis
DJ
08/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/14NOVARTIS : Replaces Two Researchers Amid Data Scandal
DJ
08/14NOVARTIS : names Bulto as new head of U.S. drugs business
RE
08/12NOVARTIS : Sandoz will appeal District Court of New Jersey ruling in biosimilar ..
AQ
08/12AMGEN : Wins Patent Case on Enbrel
AQ
More news
Financials (USD)
Sales 2019 46 921 M
EBIT 2019 13 831 M
Net income 2019 9 621 M
Debt 2019 17 640 M
Yield 2019 3,32%
P/E ratio 2019 20,9x
P/E ratio 2020 21,4x
EV / Sales2019 4,74x
EV / Sales2020 4,39x
Capitalization 205 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 94,18  $
Last Close Price 89,36  $
Spread / Highest target 20,2%
Spread / Average Target 5,40%
Spread / Lowest Target -9,84%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS17.81%202 958
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
PFIZER-21.01%190 711